Lyell Immunopharma (LYEL) Free Cash Flow (2020 - 2026)
Lyell Immunopharma recorded quarterly Free Cash Flow of -$38.6 million in Q1 2026, down 18.57% quarter-over-quarter from -$32.6 million in Q4 2025, and up 29.68% year-over-year from -$29.8 million in Q1 2025.
Lyell Immunopharma's Free Cash Flow history runs 7 years deep, the most recent figure standing at -$38.6 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 29.68% year-over-year to -$38.6 million; the TTM figure through Mar 2026 stood at -$134.5 million (up 23.31% YoY), while the FY2025 annual figure was -$150.8 million, up 7.22% from the prior year.
- Free Cash Flow came in at -$38.6 million for Q1 2026 at Lyell Immunopharma, down from -$32.6 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$21.9 million in Q4 2022 to a low of -$61.1 million in Q2 2022.
- A 5-year average of -$40.4 million and a median of -$38.8 million in 2023 frame the typical range for Free Cash Flow.
- On a YoY basis, Free Cash Flow climbed as much as 76.53% in 2022 and fell as far as 413.8% in 2022.
- Lyell Immunopharma's Free Cash Flow stood at -$21.9 million in 2022, then sank by 85.69% to -$40.7 million in 2023, then fell by 15.5% to -$47.0 million in 2024, then surged by 30.68% to -$32.6 million in 2025, then fell by 18.57% to -$38.6 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$38.6 million, -$32.6 million, and -$28.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Lyell Immunopharma | 379.11 Mn | 379.11 Mn | - | -38.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.60 Mn |
| Mar 31, 2026 | -38.60 Mn |
| Dec 31, 2025 | -32.56 Mn |
| Dec 31, 2025 | -32.56 Mn |
| Sep 30, 2025 | -28.64 Mn |
| Sep 30, 2025 | -28.64 Mn |
| Jun 30, 2025 | -34.72 Mn |
| Jun 30, 2025 | -34.72 Mn |
| Mar 31, 2025 | -54.89 Mn |
| Mar 31, 2025 | -54.89 Mn |
| Dec 31, 2024 | -46.97 Mn |
| Dec 31, 2024 | -46.97 Mn |
| Sep 30, 2024 | -35.10 Mn |
| Sep 30, 2024 | -35.10 Mn |
| Jun 30, 2024 | -38.43 Mn |
| Jun 30, 2024 | -38.43 Mn |
| Mar 31, 2024 | -42.05 Mn |
| Mar 31, 2024 | -42.05 Mn |
| Dec 31, 2023 | -40.66 Mn |
| Dec 31, 2023 | -40.66 Mn |
| Sep 30, 2023 | -37.66 Mn |
| Sep 30, 2023 | -37.66 Mn |
| Jun 30, 2023 | -38.80 Mn |
| Jun 30, 2023 | -38.80 Mn |
| Mar 31, 2023 | -46.61 Mn |
| Mar 31, 2023 | -46.61 Mn |
| Dec 31, 2022 | -21.90 Mn |
| Dec 31, 2022 | -21.90 Mn |
| Sep 30, 2022 | -39.89 Mn |
| Sep 30, 2022 | -39.89 Mn |
| Jun 30, 2022 | -61.13 Mn |
| Jun 30, 2022 | -61.13 Mn |
| Mar 31, 2022 | -47.96 Mn |
| Mar 31, 2022 | -47.96 Mn |
| Dec 31, 2021 | -93.29 Mn |
| Dec 31, 2021 | -93.29 Mn |
| Sep 30, 2021 | 12.71 Mn |
| Sep 30, 2021 | 12.71 Mn |
| Jun 30, 2021 | -58.39 Mn |
| Jun 30, 2021 | -58.39 Mn |
| Mar 31, 2021 | -52.79 Mn |
| Mar 31, 2021 | -52.79 Mn |
| Dec 31, 2020 | -12.87 Mn |
| Dec 31, 2020 | -12.87 Mn |
| Sep 30, 2020 | -41.79 Mn |
| Sep 30, 2020 | -41.79 Mn |